{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Pancreas&page=17",
    "query": {
      "condition": "Metastatic Adenocarcinoma of the Pancreas",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 429,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Pancreas&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Pancreas&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:39:47.218Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01227018",
      "title": "PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Pancreas",
        "Recurrent Pancreatic Cancer",
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "STA-9090",
          "type": "DRUG"
        },
        {
          "name": "Radiologic imaging",
          "type": "RADIATION"
        },
        {
          "name": "blood draw",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2010-12",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-07-23",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 2,
      "location_summary": "Memphis, Tennessee • Nashville, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01227018"
    },
    {
      "nct_id": "NCT00012220",
      "title": "Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 259,
      "start_date": "2001-01",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 75,
      "location_summary": "Anniston, Alabama • La Jolla, California • San Diego, California + 55 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00012220"
    },
    {
      "nct_id": "NCT01771146",
      "title": "Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pancreas Cancer",
        "Localized Pancreas Cancer",
        "Non-metastatic Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "FOLFIRINOX Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-10",
      "completion_date": "2020-09",
      "has_results": false,
      "last_update_posted_date": "2017-01-31",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01771146"
    },
    {
      "nct_id": "NCT06119217",
      "title": "Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "TTX-030, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, budigalimab, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Nab-Paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Trishula Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2024-03-25",
      "completion_date": "2026-03-06",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 28,
      "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Bakersfield, California + 25 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06119217"
    },
    {
      "nct_id": "NCT00005860",
      "title": "Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "floxuridine",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-04-26",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005860"
    },
    {
      "nct_id": "NCT04703920",
      "title": "Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Metastatic Ovarian Carcinoma",
        "Metastic or Unresectable Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "Belinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-03-04",
      "completion_date": "2025-01-02",
      "has_results": false,
      "last_update_posted_date": "2025-01-23",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04703920"
    },
    {
      "nct_id": "NCT03697239",
      "title": "High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer",
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Pancreatic Adenocarcinoma Resectable",
        "Pancreatic Ductal Adenocarcinoma",
        "Pancreatic Metastasis"
      ],
      "interventions": [
        {
          "name": "Ascorbic Acid",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel protein-bound",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hitendra Patel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-06",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03697239"
    },
    {
      "nct_id": "NCT04233866",
      "title": "Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma",
        "Stage IV Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2020-08-26",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 760,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 501 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04233866"
    },
    {
      "nct_id": "NCT03331562",
      "title": "A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreas Adenocarcinoma",
        "Advanced Pancreatic Cancer",
        "Metastatic Pancreatic Cancer",
        "Metastatic Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "paricalcitol",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Translational Genomics Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-12-27",
      "completion_date": "2020-07-10",
      "has_results": true,
      "last_update_posted_date": "2022-12-27",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Westwood, Kansas + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03331562"
    },
    {
      "nct_id": "NCT07573215",
      "title": "Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "PDAC",
        "PDAC - Pancreatic Ductal Adenocarcinoma",
        "Metastatic Pancreas Adenocarcinoma",
        "Pancreatic Cancer",
        "Pancreatic Cancer Metastatic",
        "Pancreatic Adenocarcinoma Metastatic",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Adenosquamous Carcinoma"
      ],
      "interventions": [
        {
          "name": "daraxonrasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-15T17:39:47.218Z",
      "location_count": 256,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 198 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07573215"
    }
  ]
}